Moderate-to-severe Alzheimer's Disease
Conditions
Brief summary
A multicenter, randomized, double-blind, active-controlled, phase III clinical trial to evaluate the efficacy and safety of BPDO-1603 in patients with moderate-to-severe Alzheimer's disease
Interventions
DRUGBPDO-1603
Arm1 : 1 tablet of the test drug, and 1 tablet of placebo reference drug Arm2 : 1 tablet of the reference drug, and 1 tablet of placebo test drug
Sponsors
Hyundai Pharmaceutical Co., LTD.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
45 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* A voluntary, written informed consent from the patient or the patient´s representative. * Male or female patients ≥ 45 years of age as of the date of informed consent. * Diagnosed with probable AD according to the National Institute on Aging-Alzheimer's Association \[NIA-AA (2011)\] criteria. * MMSE score of ≥ 5 and ≤ 20 during screening period. * CDR-GS of 2 \ 3 or GDS of 4 \ 7 during screening period. * Ongoing cholinesterase inhibitor therapy with stable dose of 10 mg/day donepezil hydrochloride for more than 12 weeks (inclusive) prior to screening, and can continue this therapy until randomization without any change in the dosage regimen of donepezil hydrochloride.
Exclusion criteria
* Magnetic resonance imaging (MRI) or computed tomography (CT) findings obtained within the past 12 months (ie, 48 weeks) from screening or at screening, as a cause of dementia other than probable AD. * History of other organic disease, such as vascular dementia, CNS infections (e.g., human immunodeficiency virus \[HIV\], syphilis), head injury, Creutzfeldt-Jakob disease, Niemann-Pick's disease, Huntington's disease, Parkinson's disease, epilepsy, or stroke. * Evidence of other neurological disorders which include seizure disorder that may interfere with the patient's cognition or ability to perform the study procedures. * Use of Memantine Hydrochloride within 1 month prior to screening
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in SIB total scores | from baseline to Week 24 |
| CIBIC-plus total score | at Week 24 (Baseline score will be from CIBIS |
Countries
South Korea
Contacts
Primary ContactNara LEE
Backup ContactSumin SON
Outcome results
None listed